The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 24, 2015

Filed:

Oct. 08, 2013
Applicant:

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

Inventors:

Lewis T. Williams, Mill Valley, CA (US);

Elizabeth Bosch, Cupertino, CA (US);

Stephen K. Doberstein, San Francisco, CA (US);

Kevin Hestir, Kensington, CA (US);

Diane Hollenbaugh, Mountain View, CA (US);

Ernestine Lee, San Francisco, CA (US);

Minmin Qin, Pleasanton, CA (US);

Ali Sadra, San Mateo, CA (US);

Justin Wong, Oakland, CA (US);

Ge Wu, La Canada, CA (US);

Hongbing Zhang, Albany, CA (US);

Assignee:

FIVE PRIME THERAPEUTICS, INC., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01); C07K 14/50 (2006.01); A61K 47/48 (2006.01); C07K 14/71 (2006.01); C07K 14/765 (2006.01); C07K 16/28 (2006.01); C07K 17/08 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48369 (2013.01); A61K 45/06 (2013.01); A61K 47/48415 (2013.01); C07K 14/71 (2013.01); C07K 14/765 (2013.01); C07K 16/2863 (2013.01); C07K 17/08 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01);
Abstract

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.


Find Patent Forward Citations

Loading…